National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 19213 [2016-07497]
Download as PDF
Federal Register / Vol. 81, No. 64 / Monday, April 4, 2016 / Notices
Dated: March 24, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Child Neurology K12
Review.
Date: April 15, 2016.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: William C. Benzing, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Bethesda, MD 20892–
9529, 301–496–0660, lbenzingw@
mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; P01 Review.
Date: April 29, 2016.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Natalia Strunnikova,
Ph.D., Scientific Review Administrator,
Scientific Review Branch, NINDS/NIH/
DHHS, Neuroscience Center, 6001 Executive
Blvd., Suite 3204, MSC 9529, Bethesda, MD
20892–9529, 301–402–0288,
Natalia.strunnikova@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
VerDate Sep<11>2014
19:03 Apr 01, 2016
Jkt 238001
[FR Doc. 2016–07497 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, April
13, 2016, 01:00 p.m. to April 13, 2016,
04:00 p.m., National Institutes of Health,
6701 Rockledge Drive, Bethesda, MD
20892 which was published in the
Federal Register on March 23, 2016, 81
FR 15543.
The meeting will be held on April 7,
2016 at 12:00 p.m.–4:00 p.m. The Panel
Name of the meeting will be
‘‘Neurophysiology’’. The location
remains the same. The meeting is closed
to the public.
Dated: March 25, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07480 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive License: Therapeutics for
Multiple Sclerosis, Amyotrophic
Lateral Sclerosis and Certain Other
CNS Disorders
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institute of
Neurological Disorders and Stroke
(NINDS), National Institutes of Health
(NIH), Department of Health and Human
Services, is contemplating the grant of a
start-up exclusive license to Great Lakes
Neuroscience, Inc., which is located in
Illinois, to practice the inventions
embodied in the following patents: U.S.
Patent 8,597,660, issued December 3,
2013 (HHS reference E–144–2010/0–
US–02).
The patent rights in these inventions
have been assigned to the United States
SUMMARY:
PO 00000
Frm 00102
Fmt 4703
Sfmt 4703
19213
of America. The prospective start-up
exclusive license territory may be
worldwide and the field of use may be
limited to therapeutics for Multiple
sclerosis, Acute Disseminated
Encephalomyelitis (ADEM), Balo’s
disease, Clinically Isolated Syndrome,
HTLV–1 Associated Myelopathy (HAM),
Neuromyelitis optica and NMO
spectrum disorder, Schilder’s disease,
Traverse myelitis, amyotrophic lateral
sclerosis and other motor neuron
diseases as follows: progressive bulbar
palsy, primary lateral sclerosis,
progressive muscular atrophy, spinal
muscular atrophy, Kennedy’s disease,
and post polio syndrome.
DATES: Only written comments and/or
applications for a license which are
received by NINDS Technology Transfer
on or before April 19, 2016 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated start-up exclusive license
should be directed to: Susan Ano, Ph.D.,
NINDS Technology Transfer, 31 Center
Drive, Suite 8A52, MS2540, Bethesda,
MD 20892; Telephone: (301) 435–5515;
Email: anos@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This
invention discloses treating
neurodegenerative diseases by
administering cyclin dependent kinase
5 (Cdk5) inhibitory peptides derived
from P35, the activator of Cdk5.
Abnormally hyperactive Cdk5 has been
shown to be associated with a variety of
neurodegenerative disorders. This
invention describes isolated peptide
fragments, pharmaceutical compositions
and methods for use of such for treating
subjects with a neurodegenerative
disease, such as Alzheimer’s disease
(AD), Amyotrophic Lateral Sclerosis
(ALS) and Parkinson’s disease (PD). An
inhibitory fragment, TFP5, disclosed in
this invention, has been shown to
ameliorate symptoms of AD in disease
animal models without any evidence of
toxicity. In particular, TFP5 treatment of
rat cortical neurons reduced
hyperactivation of Cdk5 upon neuronal
stress and insults. Following
intraperitoneal (ip) injection, TFP5 was
capable of crossing the blood-brain
barrier and localizing within the brain
where it was found to rescue memory
deficits and pathology in a double
transgenic mouse (APP/PS1) AD model.
The prospective start-up exclusive
license may be granted unless within
fifteen (15) days from the date of this
published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 81, Number 64 (Monday, April 4, 2016)]
[Notices]
[Page 19213]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-07497]
[[Page 19213]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Child Neurology K12 Review.
Date: April 15, 2016.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: William C. Benzing, Ph.D., Scientific Review
Administrator, Scientific Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529,
Bethesda, MD 20892-9529, 301-496-0660, lbenzingw@mail.nih.gov.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; P01 Review.
Date: April 29, 2016.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Natalia Strunnikova, Ph.D., Scientific Review
Administrator, Scientific Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529,
Bethesda, MD 20892-9529, 301-402-0288, Natalia.strunnikova@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS)
Dated: March 24, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-07497 Filed 4-1-16; 8:45 am]
BILLING CODE 4140-01-P